Search

Displaying results 4751 - 4760 of 10000 in total
  1. Drug

    Cyanocobalamin Co-60

    go.drugbank.com/drugs/DB09387
    ApprovedWithdrawn

    Cyanocobalamin Co-60 was used for the diagnosis of pernicious anemia, but now it is withdrawn from the market in the US for unknown reasons. … Cyanocobalamin Co-60 is an analog of Vitamin B12 labeled with Co60.

  2. Drug

    Phenoxypropazine

    go.drugbank.com/drugs/DB09251
    ApprovedWithdrawn

    It was marketed as an antidepressant in 1961 but was later withdrawn in 1966 because of its hepatotoxic potential. … Phenoxypropazine is a non-selective and irreversible monoamine oxidase enzyme inhibitor (MAOI), belonging to the _hydrazine_ chemical class.

  3. Drug

    KIN-3248

    go.drugbank.com/drugs/DB17587
    Investigational

    mutations in the kinase domain of FGFR. … It was designed to mainly target FGFR2 and FGFR3 alterations, which act as oncogenic drivers in 10-20% of cholangiocarcinoma and 20-35% of urothelial cancers, respectively.

  4. Drug

    Bexotegrast

    go.drugbank.com/drugs/DB16515
    Investigational

    In addition, the compound is also currently in Phase 2a trials (NCT04565249) for the treatment of COVID-19 related acute respiratory distress syndrome[L31713]. … The compound was granted orphan drug designation by the US FDA in August 2018 for treatment of IPF, and Pliant Therapeutics recently raised $100 million in Series C financing to support further clinical

    Synonyms: (S)-4-[(2-Methoxyethyl)[4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butyl]amino]-2-[(quinazolin-4-yl)amino]butanoic acid, (2S)-4-(2-METHOXYETHYL-(4-(5,6,7,8-TETRAHYDRO-1,8-NAPHTHYRIDIN-2-YL)BUTYL)AMINO)-2-(QUINAZOLIN-4-YLAMINO)BUTANOIC ACID
  5. Drug

    P54

    go.drugbank.com/drugs/DB05451
    Experimental

    It inhibits the induction of the enzyme NFkB, thereby inhibiting downstream inflammatory genes such as COX II and iNOS.

  6. Drug

    Oportuzumab monatox

    go.drugbank.com/drugs/DB05319
    Investigational

    VB4-845 is studied in the treatment of certain types of head and neck cancer. VB4-845 is made by linking a monoclonal antibody fragment to a toxic protein that may kill cancer cells. … VB4-845 is a fusion protein containing humanized scFv specific for the epithelial cell adhesion molecule, Ep-CAM, a tumor cell-associated target highly expressed on carcinoma cells of epithelial origin

  7. Drug

    BNC105

    go.drugbank.com/drugs/DB06313
    Investigational

  8. Drug

    Phenobarbital

    go.drugbank.com/drugs/DB01174
    ApprovedInvestigational

    It promotes binding to inhibitory gamma-aminobutyric acid subtype receptors, and modulates chloride currents through receptor channels. It also inhibits glutamate induced depolarizations.

    Products: Barbilixir Elx 4mg/ml, FENOBARBITALSODICO 40 MG/ML
  9. Drug

    Phenylbutazone

    go.drugbank.com/drugs/DB00812
    ApprovedVet approvedWithdrawn

    It is especially effective in the treatment of ankylosing spondylitis. It also is useful in rheumatoid arthritis and Reiter's syndrome (investigational indication). … Although phenylbutazone is effective in gouty arthritis, risk/benefit considerations indicate that this drug should not be employed for this disease. (From AMA Drug Evaluations Annual, 1994, p1822)

  10. Drug

    ARG098

    go.drugbank.com/drugs/DB06338
    Experimental

    ARG098 (anti-Fas IgM monoclonal antibody) was studied in a Phase I clinical trial in 2007 involving patients with rheumatoid arthritis.